Zacks Research Weighs in on Charles River Laboratories International, Inc.'s Q4 2024 Earnings (NYSE:CRL)

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Zacks Research increased their Q4 2024 earnings per share estimates for Charles River Laboratories International in a report released on Monday, April 29th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $3.21 for the quarter, up from their prior estimate of $3.20. The consensus estimate for Charles River Laboratories International's current full-year earnings is $11.01 per share. Zacks Research also issued estimates for Charles River Laboratories International's Q4 2025 earnings at $3.33 EPS.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.39 by $0.07. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business's quarterly revenue was down 7.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.98 earnings per share.

Other research analysts also recently issued reports about the stock. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an "outperform" rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. upped their target price on Charles River Laboratories International from $270.00 to $280.00 and gave the company an "overweight" rating in a report on Thursday, February 15th. Guggenheim cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating in a research report on Thursday, February 15th. TheStreet upgraded shares of Charles River Laboratories International from a "c+" rating to a "b-" rating in a research note on Friday, March 1st. Finally, Argus upped their target price on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a "buy" rating in a research report on Monday, March 18th. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $253.23.

Charles River Laboratories International Stock Down 1.3 %

NYSE CRL traded down $3.10 during mid-day trading on Tuesday, reaching $229.00. 506,845 shares of the company's stock traded hands, compared to its average volume of 547,998. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. Charles River Laboratories International has a 1-year low of $161.65 and a 1-year high of $275.00. The company has a fifty day simple moving average of $253.22 and a 200-day simple moving average of $223.32. The company has a market cap of $11.80 billion, a price-to-earnings ratio of 24.86, a P/E/G ratio of 1.79 and a beta of 1.40.

Insider Transactions at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the firm's stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company's stock, valued at approximately $626,155.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, VP William D. Barbo sold 4,050 shares of the firm's stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the sale, the vice president now owns 22,879 shares of the company's stock, valued at $5,685,431.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Shannon M. Parisotto sold 5,882 shares of the firm's stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company's stock, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock valued at $3,693,663 in the last three months. 1.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Charles River Laboratories International

Hedge funds and other institutional investors have recently modified their holdings of the business. VisionPoint Advisory Group LLC boosted its position in Charles River Laboratories International by 105.7% during the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company's stock valued at $28,000 after purchasing an additional 74 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Charles River Laboratories International during the third quarter valued at $37,000. Operose Advisors LLC acquired a new stake in Charles River Laboratories International during the third quarter valued at $42,000. Brown Brothers Harriman & Co. boosted its position in Charles River Laboratories International by 76.0% during the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company's stock valued at $52,000 after purchasing an additional 95 shares during the last quarter. Finally, Sunbelt Securities Inc. boosted its position in Charles River Laboratories International by 1,072.7% during the first quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company's stock valued at $70,000 after purchasing an additional 236 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).